Through our own work and in partnerships, we accelerate healthcare innovation by transforming promising life science ideas into life-changing medical breakthroughs for patients.

NEWS
LifeArc welcomes Stéphane Maikovsky as Interim CEO

LifeArc, the self-funded, not-for-profit medical research organisation today announced the appointment of Stéphane Maikovsky as Interim Chief Executive Officer (CEO), succeeding Dr Melanie Lee who stepped down from the role last month. Stéphane joined LifeArc as Chief Financial Officer (CFO) and Trustee in June 2022 to lead the organisation’s Finance, Investment, Early Ventures, Information Technology […]
NEWS
Catriona Crombie talks to Rare Revolution magazine
£100m to improve the lives of people living with rare disease
New UK-based research project brings together world-leading institutions
LifeArc strengthens Board of Trustees with new appointments
New programme to move potential MND drugs into clinical trials faster
LifeArc and Sarcoma UK fund research to guide treatment decisions in rare cancer
New partnership with PrecisionLife as part of the MND Translational Challenge
LifeArc & Cystic Fibrosis Trust announce new £15m research funding
LifeArc launches £40m funding call to create Translational Rare Disease Centres
Researchers
We can help to fund, develop and protect your academic research.
Working with TTOs
Our IP management skills can help protect and develop your medical research
Funding early stage research
Support for progression of medical science
Diagnostics development
Collaborative diagnostics development and validation
Drug discovery
As a charity we want to make sure your research reaches patients and minimise cost and risk for you
MRC
Support for Medical Research Council scientists
Charities
By working together we can increase our impact
Helping charities
We help fellow charities fund, resource and develop medical research.
Campaigning together
We work with partners to maximise our impact on transforming science into benefits for patients.
Technologies and intellectual property
We have a wide range of technologies available for licensing or further collaborative development.
Antibody humanisation
Our antibody engineering expertise has helped to put humanised antibody drugs on the market.